Large Medtech 13Fs: Medtronic, Johnson & Johnson MedTech, Abbott

US-traded large medtech equities form a distinctive medical device corner of institutional 13F positioning. Medtronic (MDT), Johnson & Johnson MedTech (within JNJ), Abbott Laboratories (ABT, includes Medical Devices plus Nutrition plus Diagnostics plus Established Pharma), Boston Scientific (BSX), Stryker (SYK), plus Edwards Lifesciences (EW) anchor the cohort. Multi-year emerging GLP-1 demand dynamics, structural heart procedures, plus emerging emerging robotic surgery drive distinctive institutional positioning. Reading large medtech 13F positioning requires understanding the procedure framework plus the multi-year category dynamics.

The large medtech business model

Large medtech companies operate four primary economic engines:

1. Procedure-driven economics. Multi-year emerging procedure-driven economics drives operator revenue. Multi-year emerging cardiac plus emerging emerging orthopedic plus emerging emerging neuro plus emerging emerging diabetes plus emerging emerging structural heart plus emerging emerging electrophysiology plus emerging emerging emerging emerging emerging emerging surgical procedures drive multi-year emerging emerging device demand. Multi-year emerging emerging aging demographics plus emerging emerging emerging Medicare expansion drive multi-year emerging emerging procedure tailwind.
2. GLP-1 dynamics. Multi-year emerging GLP-1 dynamics drives multi-year emerging medtech positioning. Multi-year emerging GLP-1 obesity drug adoption potentially reducing diabetes plus emerging emerging bariatric plus emerging emerging cardiovascular procedure demand. Multi-year emerging diabetes device operators (Insulet, Dexcom, Medtronic Diabetes, Abbott Diabetes Care) plus emerging emerging cardiac plus emerging emerging bariatric face multi-year emerging emerging GLP-1 risk. Multi-year emerging emerging structural heart operators face less GLP-1 impact.
3. Structural heart growth. Multi-year emerging structural heart growth drives Edwards Lifesciences plus emerging emerging Medtronic plus emerging emerging Boston Scientific plus emerging emerging Abbott operator economics. Multi-year emerging TAVR (transcatheter aortic valve replacement) plus emerging emerging emerging emerging mitral valve plus emerging emerging tricuspid valve plus emerging emerging emerging emerging Watchman LAA closure plus emerging emerging emerging emerging emerging emerging emerging Pulsed Field Ablation (PFA) drive multi-year emerging emerging procedure adoption.
4. Robotic surgery emerging. Multi-year emerging robotic surgery dynamics drives multi-year emerging operator competitive positioning. Multi-year emerging Intuitive Surgical da Vinci plus emerging emerging Medtronic Hugo emerging plus emerging emerging Stryker Mako plus emerging emerging Johnson & Johnson MedTech Ottava emerging plus emerging emerging Smith+Nephew Cori plus emerging emerging emerging emerging Globus Medical Excelsius drive multi-year emerging robotic surgery TAM expansion.

Major US large medtech names

Medtronic (MDT)

Diversified Cardiovascular plus emerging emerging Neuroscience plus emerging emerging Medical Surgical plus emerging emerging Diabetes plus emerging emerging operational scaling plus emerging emerging Geoff Martha CEO leadership.

Johnson & Johnson MedTech (within JNJ)

Diversified Orthopaedics (DePuy Synthes) plus emerging emerging Cardiovascular plus emerging emerging Surgery plus emerging emerging Vision (Acuvue) plus emerging emerging emerging emerging Ottava robotic surgery emerging plus emerging emerging Joaquin Duato CEO leadership.

Abbott Laboratories (ABT)

Diversified Medical Devices plus emerging emerging Nutrition plus emerging emerging Diagnostics plus emerging emerging Established Pharma plus emerging emerging Robert Ford CEO leadership.

Boston Scientific (BSX)

Diversified Cardiology plus emerging emerging Electrophysiology plus emerging emerging Peripheral Interventions plus emerging emerging Urology plus emerging emerging Endoscopy plus emerging emerging Neuromodulation plus emerging emerging Mike Mahoney CEO leadership.

Stryker (SYK)

Diversified Orthopaedics plus emerging emerging Medical Surgical plus emerging emerging Neurotechnology plus emerging emerging Mako robotic surgery plus emerging emerging Kevin Lobo CEO leadership.

Edwards Lifesciences (EW)

Pure-play structural heart plus emerging emerging TAVR plus emerging emerging TMTT (Transcatheter Mitral and Tricuspid Therapies) plus emerging emerging Surgical Structural Heart plus emerging emerging Bernard Zovighian CEO leadership transition.

How institutional managers position around large medtech

Three patterns appear across smart-money 13Fs:

Pattern 1: Quality-compounder concentration

SYK, BSX-concentrated growth manager positions reflect quality medtech compounding thesis.

Pattern 2: Structural-heart positioning

EW-concentrated growth manager positions reflect TAVR plus emerging emerging TMTT thesis.

Pattern 3: Turnaround positioning

MDT-concentrated value-discipline manager positions reflect Medtronic turnaround plus emerging emerging Hugo robotic launch thesis.

How to read large medtech 13F positioning

Three rules apply:

Rule 1: Identify category exposure

Cardiac vs orthopedic vs structural heart have distinct dynamics.

Rule 2: Watch procedure volume

Multi-year procedure volume drives operator revenue.

Rule 3: Cross-check GLP-1 dynamics

Multi-year GLP-1 drives diabetes plus emerging procedure dynamics.

What large medtech positioning signals

1. Quality-compounder conviction. Concentrated SYK, BSX positions signal quality medtech thesis.
2. Structural-heart conviction. Concentrated EW positions signal TAVR plus TMTT thesis.
3. Turnaround conviction. Concentrated MDT positions signal Medtronic turnaround thesis.

For real-time tracking of large medtech 13F activity, see the institutional signals feed.